Form 4: Protagonist Therapeutics CFO Asif Ali Reports Stock Sales and Option Exercises
SEC Form 4
Asif Ali, CFO of Protagonist Therapeutics, reports the sale of common stock and the exercise of stock options.
Summary
- On September 11, 2024, Asif Ali, the Chief Financial Officer of Protagonist Therapeutics, engaged in transactions involving the company's stock.
- Ali sold 2,203 shares of common stock at $44.59 per share and another 12,000 shares at a weighted average price of $44.47 per share.
- He also exercised options to acquire 6,000 shares at $19.19 per share and another 6,000 shares at $12.17 per share.
- Following these transactions, Ali directly owns 34,960 shares of Protagonist Therapeutics common stock.
- He also holds options to purchase 76,500 shares at $19.19 and 45,750 shares at $12.17.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock.
Stakeholder Impact
- The stock sales by the CFO may be perceived differently by shareholders, with some potentially viewing it as a lack of confidence in the company's future prospects, while others may see it as a routine part of personal financial management.
Key Dates
| Date | Description |
|---|---|
| 04/18/2022 | Date stock option was granted to the Reporting Person. |
| 01/16/2023 | Date stock option was granted to the Reporting Person. |
| 04/18/2023 | One quarter of stock option granted on April 18, 2022 vested. |
| 09/11/2024 | Date of stock sales and option exercises. |
| 09/13/2024 | Date of Form 4 filing. |
| 04/18/2026 | Remaining three quarters of stock option granted on April 18, 2022 vest in equal monthly installments through this date. |
| 04/18/2032 | Expiration date of stock options granted on April 18, 2022. |
| 01/15/2033 | Expiration date of stock options granted on January 16, 2023. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.